budipine budipine budipine (brand name parkinsan) is an antiparkinson agent marketed for the treatment of parkinson's disease. budipineclinical dataahfs/drugs.cominternational drug namesatc coden04bx03 (who) identifiers iupac name 1-tert-butyl-4,4-diphenylpiperidine cas number57982-78-2 ypubchem cid68778chemspider62021 yuniil9026opi2zkeggd07306 ychemblchembl334491 ycomptox dashboard (epa)dtxsid20206709 echa infocard100.055.494 chemical and physical dataformulac21h27nmolar mass293.454 g·mol−13d model (jsmol)interactive image smiles c1(ccccc1)c3(c2ccccc2)ccn(c(c)(c)c)cc3 inchi inchi=1s/c21h27n/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13h,14-17h2,1-3h3 ykey:qihluzafssmxhq-uhfffaoysa-n y (verify) while its exact mechanism of action is not well characterized, it is believed to be an nmda receptor antagonist, but also promoting the synthesis of dopamine. because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment. synthesis budipine can be prepared from the 1-tert-butyl-4-piperidone directly by treatment with benzene in the presence triflic acid. this method of synthesis enables a 99% yield of product. thieme synthesis: 4-phenyl-1-t-butyl-4-piperidinol, (1) 1-t-butyl-3-benzoyl-4-phenyl-4-piperidinol (3)